Movement DisordersNeurosciencePeer-reviewed journal article
GDNF/RET signaling pathway activation eliminates Lewy Body pathology in midbrain dopamine neurons
Piotr ChmielarziD, Şafak EriD, Julia KonovalovaiD, Laura Bandrés, Irena HlushchukiD, Katrina AlbertiD, Anne E. PanhelaineniD, Kelvin C. LukiD, Mikko AiravaaraiD, Andrii DomanskyiiD
Abstract
Neurodegenerative diseases are associated with proteostasis disturbances and accumulation of fibrillar proteins into insoluble aggregates. Progressive age-related degeneration of dopamine neurons is a primary cause of motor dysfunctions in Parkinsons disease (PD) and substantial evidence supports critical involvement of -synuclein (-syn) in the etiology of PD. -syn is a cytosolic protein present in high concentrations in pre-synaptic neuronal terminals and a primary constituent of intracellular protein aggregates known as Lewy Neurites or Lewy Bodies. Progression of Lewy pathology is a characteristic feature in the PD brains caused by the prion-like self-templating properties of misfolded -syn. Modelling Lewy pathology progression with application of exogenously prepared -syn preformed fibrils, we discovered that glial cell line-derived neurotrophic factor (GDNF) prevented formation of -syn aggregates in dopamine neurons in culture and in vivo after viral vector expression of GDNF. These effects were abolished by CRISPR/Cas9-mediated deletion of receptor tyrosine kinase Ret, the major GDNF signaling pathway. Similar to GDNF, expression of mutated constitutively active RET (RET_MEN2B) was able to protect dopamine neurons. GDNF protection against -syn pathology progression was abolished by Src and attenuated by Akt pathway inhibitors. For the first time, we have shown the neurotrophic factor-mediated protection against the misfolded -syn propagation in dopamine neurons, uncovered underlying receptor and intracellular signaling pathways. These results for the first time demonstrate that activation of GDNF/RET signaling can be an effective therapeutic approach to prevent Lewy pathology spread at early stages of PD.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=145 HEIGHT=200 SRC=\"FIGDIR/small/752899v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (57K):\norg.highwire.dtl.DTLVardef@1f5109dorg.highwire.dtl.DTLVardef@15e4a2org.highwire.dtl.DTLVardef@15571c8org.highwire.dtl.DTLVardef@a10f7d_HPS_FORMAT_FIGEXP M_FIG C_FIG
- Citations
- 60
- FWCI
- 3.25
- Field percentile
- top 6%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PKB/AKT attenuates Lewy Body-like pathology in primary neurons via Cathepsins B and D
Julia Konovalova, Şafak Er, … Piotr Chmielarz·bioRxiv·Sep 23, 2022
- α-Synuclein aggregates in corticostriatal terminals impair glutamatergic transmission in the absence of neurodegeneration
Charlotte F. Brzozowski, Zoe N. Fokakis, … Laura A. Volpicelli‐Daley·bioRxiv·Aug 7, 2026
- Astrocytic Cathepsin D truncates α-synuclein and promotes Lewy neurite-like aggregation in neurons
Hiroshi Hanafusa, Kota Ohashi, … Kunihiro Matsumoto·bioRxiv·Oct 3, 2025
- GDNF receptor agonist supports dopamine neurons in vitro and protects their function in animal model of Parkinson's disease.
Arun Kumar Mahato, Juho‐Matti Renko, … Märt Saarma·bioRxiv·Feb 4, 2019
- A dual hit of α-synuclein internalization and immune challenge leads to formation and maintenance of Lewy body-like inclusions in human dopaminergic neurons
Armin Bayati, Riham Ayoubi, … Peter Scottt McPherson·bioRxiv·May 29, 2023
- Rab27b promotes lysosomal function and alpha-synuclein clearance in neurons
Kasandra Scholz, Rudradip Pattanayak, … Talene A. Yacoubian·Journal of NeurosciencePeer-reviewed·Feb 18, 2025